WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NTLA

Based on 15 analysts offering 12 month price targets for Intellia Therapeutics Inc.
Min Forecast
$39.00+1.91%
Avg Forecast
$83.20+117.4%
Max Forecast
$120.00+213.56%

Should I buy or sell NTLA stock?

Based on 15 analysts offering ratings for Intellia Therapeutics Inc.
Strong Buy
Strong Buy
7 analysts 46.67%
Buy
6 analysts 40%
Hold
2 analysts 13.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NTLA stock forecasts and price targets.

NTLA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BMO Capital
Bottom 13%
13
BuyUpgrades$57.00+48.94%2023-03-14
Chardan Capital
Top 20%
81
Strong BuyMaintains$111.00+190.04%2023-02-27
Credit Suisse
Bottom 8%
8
BuyMaintains$76.00+98.59%2023-02-24
Oppenheimer
Top 3%
98
BuyMaintains$93.00+143.01%2023-02-24
Baird
Bottom 1%
1
HoldMaintains$42.00+9.75%2023-02-24
EF Hutton
Bottom 3%
3
Strong BuyMaintains$116.00+203.11%2023-02-24
Raymond James
Bottom 26%
26
BuyMaintains$94.00+145.62%2023-02-24
Cantor Fitzgerald
Bottom 5%
5
Strong BuyInitiates Coverage On$67.00+75.07%2023-02-01
Citigroup
Top 20%
81
HoldUpgrades$39.00+1.91%2023-01-24
SVB Leerink
Bottom 1%
1
BuyMaintains$84.00+119.49%2023-01-23

1 of 2

Forecast return on equity

Is NTLA forecast to generate an efficient return?
Company
N/A
Industry
-0.1%
Market
28.88%

Forecast return on assets

Is NTLA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.01%

NTLA earnings per share forecast

What is NTLA's earnings per share in the next 3 years based on estimates from 13 analysts?
Avg 1 year Forecast
-$5.84
Avg 2 year Forecast
-$7.25
Avg 3 year Forecast
-$7.30

NTLA revenue forecast

What is NTLA's revenue in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$57.2M+9.79%
Avg 2 year Forecast
$57.4M+10.19%
Avg 3 year Forecast
$179.0M+243.41%
NTLA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NTLA revenue growth forecast

How is NTLA forecast to perform vs Biotechnology companies and vs the US market?
Company
44.84%
Industry
40.95%
Market
8.76%
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NTLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NTLA$38.27$83.20+117.40%Strong Buy
CYTK$35.20$61.53+74.81%Strong Buy
RETA$89.38$112.67+26.05%Strong Buy
ISEE$23.81$27.33+14.80%Strong Buy
FOLD$11.54$14.75+27.82%Buy
View Top Biotech Stocks

Intellia Therapeutics Stock Forecast FAQ

Is Intellia Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: NTLA) stock is to Strong Buy NTLA stock.

Out of 15 analysts, 7 (46.67%) are recommending NTLA as a Strong Buy, 6 (40%) are recommending NTLA as a Buy, 2 (13.33%) are recommending NTLA as a Hold, 0 (0%) are recommending NTLA as a Sell, and 0 (0%) are recommending NTLA as a Strong Sell.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

What is NTLA's earnings growth forecast for 2023-2025?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.48%.

Intellia Therapeutics's earnings in 2023 is -$474,186,000.On average, 13 Wall Street analysts forecast NTLA's earnings for 2023 to be -$514,024,764, with the lowest NTLA earnings forecast at -$725,267,817, and the highest NTLA earnings forecast at -$415,444,672. On average, 8 Wall Street analysts forecast NTLA's earnings for 2024 to be -$638,130,058, with the lowest NTLA earnings forecast at -$883,700,108, and the highest NTLA earnings forecast at -$404,882,519.

In 2025, NTLA is forecast to generate -$642,530,955 in earnings, with the lowest earnings forecast at -$958,515,356 and the highest earnings forecast at -$323,025,836.

What is NTLA's revenue growth forecast for 2023-2025?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 44.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.

Intellia Therapeutics's revenue in 2023 is $52,121,000.On average, 9 Wall Street analysts forecast NTLA's revenue for 2023 to be $5,036,562,505, with the lowest NTLA revenue forecast at $1,643,294,921, and the highest NTLA revenue forecast at $10,562,152,680. On average, 8 Wall Street analysts forecast NTLA's revenue for 2024 to be $5,054,870,237, with the lowest NTLA revenue forecast at $426,887,004, and the highest NTLA revenue forecast at $13,249,340,358.

In 2025, NTLA is forecast to generate $15,754,330,902 in revenue, with the lowest revenue forecast at $2,640,538,170 and the highest revenue forecast at $41,808,521,025.

What is NTLA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: NTLA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.01%.

What is NTLA's Price Target?

According to 15 Wall Street analysts that have issued a 1 year NTLA price target, the average NTLA price target is $83.20, with the highest NTLA stock price forecast at $120.00 and the lowest NTLA stock price forecast at $39.00.

On average, Wall Street analysts predict that Intellia Therapeutics's share price could reach $83.20 by Mar 14, 2024. The average Intellia Therapeutics stock price prediction forecasts a potential upside of 117.4% from the current NTLA share price of $38.27.

What is NTLA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: NTLA) Intellia Therapeutics's current Earnings Per Share (EPS) is -$6.16. On average, analysts forecast that NTLA's EPS will be -$5.84 for 2023, with the lowest EPS forecast at -$8.24, and the highest EPS forecast at -$4.72. On average, analysts forecast that NTLA's EPS will be -$7.25 for 2024, with the lowest EPS forecast at -$10.04, and the highest EPS forecast at -$4.60. In 2025, NTLA's EPS is forecast to hit -$7.30 (min: -$10.89, max: -$3.67).

What is NTLA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: NTLA) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.